AU · rank #11 · 2026-09-11
FRE
XETRA · EUR · $28.98B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.182 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.01 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 10 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $55.59 | +24.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +19.29% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +25.4% |
| 52w high | $51.53 |
| Market cap (USD) | $28.98B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Fresenius SE is a diversified European healthcare group operating private hospitals (Helios) and infusion/nutrition/pharma businesses (Kabi), generating ~€22.5 billion in annual revenue with ~178,000 employees.
Rationale
The analyst_upside signal is strongly reinforced by a concrete catalyst — management's guidance raise to 10–15% core EPS growth — which explains the 91.7% revision agreement, 10 net upward revisions in 30 days, and 24% consensus upside, all pointing to a genuine re-rating rather than stale sentiment.
Material risks
- 1Germany's GKV Stabilization Act directly pressures Helios reimbursement rates, and if hospital margin compression offsets Kabi's gains, the EPS upgrade cycle that drives this entire thesis could stall or reverse.
- 2The last earnings surprise was -6.68%, meaning execution risk is real; the RESET program must continue delivering cost savings or the structural margin step-up narrative collapses and analyst targets will be cut, unwinding the upside signal.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.